Zeiss surgery portfolio expands

The agreent – for an undisclosed amount – to take over the Nevada-based private company was sealed on October 23, adding to the German manufacturer’s cataract surgery portfolio.IanTECH devices focus on micro-interventional cataract surgery technology and include the miLOOP lens fragmentation device, used in dense or difficult cataract surgeries. Zeiss president Dr Ludwin Monz, said cataract surgery had been dependent on phacoulsification (phaco) technology for more than five decades and that the market needs a fresh approach in the field of phaco.“We expect that IanTECH will complent our leading portfolio of equipment and consumables in cataract surgery, allowing us to offer physicians and patients a new standard of care,” he said.“The technology has the potential to simplify challenging cases, reduce risk to patients and further improve outcomes while being easy to train and adapt for surgeons.”IanTECH co-founder Profesor Sean Lanchulev told medical news site Healio.com that it was widely agreed cataract surgery had only seen incrental innovation with phacoulsification in the past 50 years.With micro-interventional technology, surgeons “can shift the entire paradigm and really create a completely different approach, optimising the surgical technique and delivering potentially better outcomes and procedures in the future,” he said.